News
Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Announcement
Horizon Scanning in Onkology - Reports
We are pleased to introduce our two new HSO reports.
DSD HSO No. 72
Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC)
DSD HSO No. 71
Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer
Newsletter
Event archive
Event
Symposium Post-marketing studies (application monitoring) in Germany and Europe - do they contribute to drug safety?
This Information is available in German only.
Newsletter
Announcement
Sponsoring of Patientinitiatives in Austria 2016. Update of the Systematic Analyses 2015 and 2014
As part of the professionalization of patients organizations and the expansion of their activities (eg. awareness campaigns, advisory services for patients and their relatives, etc.) the need for financial resources is also increasing. This need is often covered by pharmaceutical and medical device manufacturers. This update analyzed the extent of financial support for patient organizations from pharmaceutical companies in Austria in 2016. 40 of 118 PHARMIG member companies have declared donations to patient organization for the year 2016. A total sum of € 1.435.059 in grants to patient initiatives were reported by the PHARMIG member companies. Most grants (72%) were given to initiatives in the field of Oncology & Hematology, Neurology, Lung, Hemophilia, and Rheumatology.
Altogether the increase in disclosure in comparison to 2015 was much lower. The total sum of contributions even decreased by almost 20% compared to 2015.
Publication: Rapid Assessment Nr. 7b/2. Update 2017: https://eprints.aihta.at/1132
Contact: Philipp Petersen
Newsletter
Announcement
Evaluation of individual medical procedures 2017 - Reports
We are pleased to introduce our new reports.
Decison Support Documents 2017
-
DSD 104: Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD)
https://eprints.aihta.at/1128 -
DSD 105: Prostate artery embolisation for benign prostatic hyperplasia
https://eprints.aihta.at/1118 -
DSD 106: Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS
https://eprints.aihta.at/1129 -
DSD 107: Repetitive transcranial magnetic stimulation for treatment-resistant major depression
https://eprints.aihta.at/1130 -
DSD 108: Radiofrequency ablation for metastatic spinal lesions
https://eprints.aihta.at/1131
+2 Updates:
-
DSD 21/Update 2017: Percutaneous disc volume reduction – chemonucleolysis
https://eprints.aihta.at/1126 -
DSD 97/Update 2017: Leadless pacemakers for right ventricle pacing
https://eprints.aihta.at/1127
Announcement
Sponsoring of Patientinitiatives in Austria 2015. Update of the Systematic Analysis 2014
As part of the professionalization of patients organizations and the expansion of their activities (eg. awareness campaigns, advisory services for patients and their relatives, etc.) the need for financial resources is also increasing. This need is often covered by pharmaceutical and medical device manufacturers. This update analyzed the extent of financial support for patient organizations from pharmaceutical companies in Austria in 2015. 36 of 116 PHARMIG member companies have declared donations to patient organization for the year 2015. A total sum of € 1.724.683 in grants to patient initiatives were reported by the PHARMIG member companies. Most grants (68%) were given to initiatives in the field of Oncology & Hematology, Neurology, Lung, Hepatitis, and Rheumatology.
Altogether there was a significant increase in disclosure in comparison to 2014. Both the number of pharmaceutical companies that declared financial contributions and the total sum of contributions has risen by 50%.
Publication: Rapid Assessment No. 7b/1. Update 2017: https://eprints.aihta.at/1125/
Contact: Philipp Petersen
Announcement
Horizon Scanning in Onkology - Reports
We are pleased to introduce our two new HSO reports.
DSD HSO No. 70
Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC)
DSD HSO No. 69
Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer